Veraxa Biotech AG - Post de-SPAC SEC filings VRXAW
Veraxa Biotech AG - Post de-SPAC has 56 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. Its latest annual report, Form 20-F, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 15, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 29, 2026 | Oct 27, 2026 |
| 4 | Insider transaction | Oct 21, 2026 | Oct 20, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 3 | Initial insider ownership | Sep 14, 2026 | Sep 1, 2026 |
| 424B3 | Prospectus | Sep 4, 2026 | — |
| 424B3 | Prospectus | Sep 4, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 4 | Insider transaction | Aug 31, 2026 | Aug 27, 2026 |
| 4 | Insider transaction | Aug 31, 2026 | Aug 27, 2026 |
| 6-K | Current report (foreign issuer) | Aug 24, 2026 | Aug 24, 2026 |
| 3 | Initial insider ownership | Aug 20, 2026 | Jul 10, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| 424B5 | Prospectus supplement | Aug 10, 2026 | — |
| 424B5 | Prospectus supplement | Aug 10, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| F-1/A | Filing | Aug 5, 2026 | — |
| F-1/A | Filing | Aug 5, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Jul 31, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Jul 31, 2026 | — |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jun 18, 2026 | Jun 18, 2026 |
| 20-F | Annual report (foreign issuer) | Jun 16, 2026 | Dec 31, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Jun 16, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jun 16, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jun 15, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jun 15, 2026 | — |
| 6-K | Current report (foreign issuer) | Jun 11, 2026 | Jun 10, 2026 |
| CERT | Filing | Jun 10, 2026 | — |
| 8-A12B/A | Filing | Jun 10, 2026 | — |
| 3 | Initial insider ownership | Jun 10, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 10, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 9, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 9, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 9, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 9, 2026 | Jun 9, 2026 |
| 3 | Initial insider ownership | Jun 9, 2026 | Jun 9, 2026 |
| 8-A12B | Filing | Jun 9, 2026 | — |
| 424B3 | Prospectus | Feb 19, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 13, 2026 | — |
| F-4/A | Filing | Feb 13, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2026 | — |
| F-4/A | Filing | Feb 3, 2026 | — |
| CORRESP | Letter to the SEC | Nov 28, 2025 | — |
| F-4/A | Filing | Nov 28, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2025 | — |
| 425 | Filing | Sep 30, 2025 | — |
| F-4/A | Filing | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2025 | — |
| F-4/A | Filing | Jul 31, 2025 | — |
| F-4 | Filing | Jul 31, 2025 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRXA (Nasdaq), VRXAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079109
- Former names
- Veraxa Biotech Holding AG (until Aug 13, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.